Decision-making for the treatment of climacteric symptoms using the Menopause Rating Scale

Blümel, Juan E.; Arteaga, Eugenio; Parra, Joaquín Zamarro; Monsalve, Carolina; Reyes, Valentina; Vallejo, María S.; Chea, Rosa

doi:10.1016/j.maturitas.2018.02.010

Cited by 25 publications

(18 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Symptom monitoring methods could support this model, tools such as the MRS and the C-SCAT-M can help patients prioritise symptoms and identify the improvements they expect to see in the future, and this process can facilitate decision-making and patient-doctor communication. This theory corresponds with additional themes from this review, which found evidence that symptom monitoring could be useful for improving patient-doctor communication and facilitating decisions to use HRT and seek timely medical help (17)(18)(19)(20)(21)27).…”

Section: Discussionsupporting

confidence: 63%

“…Two studies involved the Women's Health Assessment Tool (WHAT), a symptom questionnaire relevant to midlife women ( 17 , 18 ). Two studies included the Menopause Rating Scale (MRS), a questionnaire developed to evaluate menopausal symptom frequency, severity, and change ( 19 , 20 ). Two studies explored The Computerised Symptom Capture Tool for Menopause [C-SCAT-M; ( 21 , 22 )].…”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Evaluating the Effects of Symptom Monitoring on Menopausal Health Outcomes: A Systematic Review and Meta-Analysis

Andrews

Hale

John

et al. 2021

Front. Glob. Womens Health

View full text Add to dashboard Cite

Evidence suggests that monitoring and appraising symptoms can result in increased engagement in medical help-seeking, improved patient-doctor communication, and reductions in symptom prevalence and severity. To date, no systematic reviews have investigated whether symptom monitoring could be a useful intervention for menopausal women. This review explored whether symptom monitoring could improve menopausal symptoms and facilitate health-related behaviours. Results suggested that symptom monitoring was related to improvements in menopausal symptoms, patient-doctor communication and medical decision-making, heightened health awareness, and stronger engagement in setting treatment goals. Meta-analyses indicated large effects for the prolonged use of symptom diaries on hot flush frequencies. Between April 2019 and April 2021, PsychInfo, EMBASE, MEDLINE, CINAHL, Cochrane, ProQuest, PsychArticles, Scopus, and Web of Science were searched. Eighteen studies met the eligibility criteria and contributed data from 1,718 participants. Included studies quantitatively or qualitatively measured the impact of symptom monitoring on menopausal populations and symptoms. Research was narratively synthesised using thematic methods, 3 studies were examined via meta-analysis. Key themes suggest that symptom monitoring is related to improvements in menopausal symptoms, improved patient-doctor communication and medical decision-making, increased health awareness, and stronger engagement in goal-setting behaviours. Meta-analysis results indicated large effects for the prolonged use of symptom diaries on hot flush frequency: 0.73 [0.57, 0.90]. This review is limited due to the low number of studies eligible for inclusion, many of which lacked methodological quality. These results indicate that symptom monitoring has potential as an effective health intervention for women with menopausal symptoms. This intervention may be beneficial within healthcare settings, in order to improve patient-doctor relations and adherence to treatment regimes. However, findings are preliminary and quality assessments suggest high risk of bias. Thus, further research is needed to support these promising outcomes.Systematic Review Registration Number:https://www.crd.york.ac.uk/prospero/display_record.php?, PROSPERO, identifier: CRD42019146270.

show abstract

Section: Discussionsupporting

confidence: 63%

Section: Resultsmentioning

confidence: 99%

Evaluating the Effects of Symptom Monitoring on Menopausal Health Outcomes: A Systematic Review and Meta-Analysis

Andrews

Hale

John

et al. 2021

Front. Glob. Womens Health

View full text Add to dashboard Cite

show abstract

“…A pooled analysis using data from 21 312 women (median age 50 years) in eight studies undertaken in the UK, USA, Australia and Japan found that the overall prevalence of vasomotor symptoms was 40%, ranging from 13% to 62% [26]. Other menopausal symptoms may include chronically disturbed sleep, which, in turn, can lead to insomnia, fatigue, irritability and difficulties with short-term memory and concentration as well as muscle and joint discomfort [27,28]. Although vasomotor symptoms usually are present for less than five years, some women will continue to flush beyond the age of 60 years [29,30,31,32].…”

Section: Menopausal Symptomsmentioning

confidence: 99%

Global consensus recommendations on menopause in the workplace: A European Menopause and Andropause Society (EMAS) position statement

Rees¹,

Bitzer²,

Cano³

et al. 2021

Maturitas

View full text Add to dashboard Cite

Introduction: Worldwide, there are 657 million women aged 45-59 and around half contribute to the labor force during their menopausal years. There is a diversity of experience of menopause in the workplace. It is shaped not only by menopausal symptoms and context but also by the workplace environment. It affects quality of life, engagement, performance, motivation and relations with employers. Aim: To provide recommendations for employers, managers, healthcare professionals and women to make the workplace environment more menopause supportive, and to improve women's wellbeing and their ability to remain in work.

show abstract

“…The validity of this scale and its content has been confirmed [15]. The MRS is a valuable international instrument for assessing menopausal symptoms that has been used in many clinical and epidemiological studies to determine the frequency and severity of menopausal symptoms in women [16]. This tool consists of 11 symptoms of menopause in three areas: somatic (4 questions), psychological (4 questions), and urogenital (3 questions).…”

Section: Methodsmentioning

confidence: 99%

The comparison of paroxetine and gabapentin in the management of postmenopausal symptoms

Veisi¹,

Azadian²,

Zangeneh³

2021

GSC Biol. and Pharm. Sci.

View full text Add to dashboard Cite

Objective: To compare the clinical efficacy of gabapentin, an anticonvulsant agent, and paroxetine, a selective serotonin reuptake inhibitor in the management of post-menopausal symptoms. Methods: In this clinical trial, two groups of patients with menopause who had hot flashes were included. One group received gabapentin (600 mg daily, 23 cases) for 8 weeks. The other group received paroxetine (one capsule daily at the morning or at bedtime, 23 cases) for 8 weeks. The MRS (Menopause Rating Scale) as well as the Beck’s Depression Inventory were used to assess the efficacy of the studied medications. Results: In paroxetine and gabapentin groups, hot flashes, sleep problems, muscle/joint pains, depression, irritability, anxiety, memory problems, and lack of concentration severity significantly decreased after 8 weeks of treatment. Only urinary problems in two treatment groups did not show any significant difference. There was no significant difference in dryness and burning sensation before and after gabapentin (P> 0.05). However, these changes were significant in paroxetine group (P <0.05). Conclusion: Both paroxetine and gabapentin were effective options in decreasing the severity of menopausal symptoms namely hot flashes, heart discomfort, sleep problems, and muscle/joint pains. In addition, the two medications had favorable results regarding psychological aspects of menopause.

show abstract

Decision-making for the treatment of climacteric symptoms using the Menopause Rating Scale

Cited by 25 publications

References 11 publications

Evaluating the Effects of Symptom Monitoring on Menopausal Health Outcomes: A Systematic Review and Meta-Analysis

Evaluating the Effects of Symptom Monitoring on Menopausal Health Outcomes: A Systematic Review and Meta-Analysis

Global consensus recommendations on menopause in the workplace: A European Menopause and Andropause Society (EMAS) position statement

The comparison of paroxetine and gabapentin in the management of postmenopausal symptoms

Contact Info

Product

Resources

About